The Study
An Open-Label Exploratory Clinical Trial Evaluating the Effects of GLS (Coptidis Rhizoma-Evodiae Fructus 2 : 1) on Fibroblast Growth Factor 21 in Patients with Nonalcoholic Fatty Liver Disease
This study is like a fair race between two treatments where people were randomly assigned to each team. It shows that one treatment (GLS) seemed to work better than the other (PPC) for fatty liver disease. But because the doctors and patients knew who got which treatment, it’s possible their expectations affected the results.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
Grown-ups with fatty liver got either a special herb mix (GLS) or a common liver pill (PPC) for 12 weeks, plus diet and exercise tips. The herb mix worked better at cleaning fat from the liver and shrinking bellies.
Where does this study sit?
Systematic Reviews & Meta-analyses
Max 100Randomized Trials
Max 90Cohort Studies
Max 72Case-Control
Max 58Cross-Sectional
Max 44Case Reports & Series
Max 30Expert Opinion
Max 563 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes, these changes mean healthier livers and lower risk of diabetes and heart disease.
- 2The herb group lost 3.45 kg vs 1.95 kg, liver fat dropped more (35.6 vs 20.8 dB/m), and bad liver enzymes and fats in blood improved more.
- 3Their body's stress hormone (FGF-21) also dropped more (32.0 vs 23.5 pg/mL).
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Evidence-based Complementary and Alternative Medicine : eCAM
Year
2022
Authors
Yang Zhang, Jian-Xing Luo, Yan-Ge Li, Hongyong Fu, Fang Yang, Xiaoyu Hu
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.